TipRanks
Advertisement
Advertisement

EPRX Stock Latest News

Eupraxia Pharmaceuticals Launches Conference Roadshow and Analyst Day to Spotlight EP-104GI
Company AnnouncementsEupraxia Pharmaceuticals Launches Conference Roadshow and Analyst Day to Spotlight EP-104GI
2d ago
6K
EPRX
Analyst Reiterates Buy on Eupraxia Pharmaceuticals, Sees Attractive Risk-Reward with Unchanged $11 Price Target Ahead of Phase 2b RESOLVE Data
PremiumRatings
Analyst Reiterates Buy on Eupraxia Pharmaceuticals, Sees Attractive Risk-Reward with Unchanged $11 Price Target Ahead of Phase 2b RESOLVE Data
4d ago
EPRX
Eupraxia Pharmaceuticals: Buy Rating Reaffirmed on Strong Phase 2b Setup and Favorable Risk-Reward After Price Target Cut to $11
PremiumRatings
Eupraxia Pharmaceuticals: Buy Rating Reaffirmed on Strong Phase 2b Setup and Favorable Risk-Reward After Price Target Cut to $11
9d ago
EPRX
Eupraxia Pharmaceuticals Hits RESOLVE Trial Enrollment Target Ahead of December Interim Data
PremiumCompany Announcements
Eupraxia Pharmaceuticals Hits RESOLVE Trial Enrollment Target Ahead of December Interim Data
9d ago
6K
EPRX
Eupraxia Pharmaceuticals reaches enrollment target for RESOLVE study
PremiumThe Fly
Eupraxia Pharmaceuticals reaches enrollment target for RESOLVE study
9d ago
EPRX
Eupraxia Pharmaceuticals Showcases EP-104GI EoE Data at Major Gastroenterology Meetings
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Showcases EP-104GI EoE Data at Major Gastroenterology Meetings
15d ago
6K
EPRX
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
Premium
Ratings
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
23d ago
EPRX
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
Premium
Ratings
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
24d ago
EPRX
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
PremiumRatings
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
24d ago
EPRX
Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial
PremiumCompany Announcements
Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial
24d ago
6K
EPRX
Eupraxia announces data from Phase 1b/2a RESOLVE study of EP-104GI
PremiumThe Fly
Eupraxia announces data from Phase 1b/2a RESOLVE study of EP-104GI
24d ago
EPRX
Wedbush bullish on Eupraxia Pharmaceuticals, initiates with an Outperform
PremiumThe Fly
Wedbush bullish on Eupraxia Pharmaceuticals, initiates with an Outperform
30d ago
EPRX
Eupraxia Pharmaceuticals initiated with an Outperform at Wedbush
PremiumThe FlyEupraxia Pharmaceuticals initiated with an Outperform at Wedbush
1M ago
EPRX
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach
Premium
Company Announcements
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach
2M ago
6K
EPRX
Eupraxia Pharmaceuticals management to meet with Oppenheimer
Premium
The Fly
Eupraxia Pharmaceuticals management to meet with Oppenheimer
2M ago
EPRX
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
PremiumRatings
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
2M ago
EPRX
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
PremiumRatings
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
2M ago
EPRX
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
PremiumThe Fly
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
2M ago
EPRX
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
PremiumThe Fly
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
2M ago
EPRX
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI
PremiumCompany AnnouncementsEupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI
2M ago
6K
EPRX
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
Premium
Ratings
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
2M ago
EPRX
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
2M ago
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >